You are here: Industry Insights > Merck

News List

Merck Reports Topline Data for Bintrafusp Alfa as Second-Line Monotherapy Treatment in Biliary Tract Cancer prnasia
March 16, 2021
Merck, a leading science and technology company, today announced topline data from the Phase II INTR@PID BTC 047 study evaluating bintrafusp alfa as a monotherapy in the second-line treatment of patients with locally advanced or metastatic biliary ...
Doctors keen to adopt novel biomarkers for immuno-oncology regimens: GlobalData expresspharma
March 16, 2021
The most promising or anticipated biomarker among high-prescribing physicians in the seven major markets was identified to be measures of tumour mutational burden.
Gilead, Merck sign pact to develop, commercialise long-acting HIV treatment combinations expresspharma
March 16, 2021
Gilead Sciences and Merck, known as MSD outside the US and Canada, announced that they have entered into an agreement to co-develop and co-commercialise long-acting treatments in HIV that combine Gilead’s investigational capsid inhibitor, lenacapavir ...
Ridgeback and Merck report preliminary data from Covid-19 trial pharmaceutical-technology
March 09, 2021
Merck and Ridgeback Biotherapeutics have reported preliminary results from a Phase IIa trial of investigational oral antiviral agent molnupiravir EIDD-2801/MK-4482 for Covid-19.
Connected drug delivery devices market to grow to $4bn by 2028 europeanpharmaceuticalreview
March 04, 2021
A new report reveals the COVID-19 pandemic, prevalence of chronic disease and increasing patient engagement will all drive adoption of connected drug delivery devices.
Merck to support manufacturing of Johnson & Johnson’s Covid-19 vaccine pharmaceutical-technology
March 04, 2021
Merck (MSD) has signed an agreement with Janssen Pharmaceuticals (JPI), one of the Janssen Pharmaceutical Companies of Johnson & Johnson, to support the manufacturing and supply of its Covid-19 vaccine.
Merck signs agreement to buy Pandion Therapeutics for $1.85bn pharmaceutical-technology
March 01, 2021
Merck has agreed to acquire biotechnology company Pandion Therapeutics for approximately $1.85bn to expand its portfolio of autoimmune disease-targeting candidates.
Merck and BioNTech to boost lipid supply for Covid-19 vaccine production pharmaceutical-technology
February 09, 2021
Merck and BioNTech have announced a further expansion of their strategic partnership to accelerate the supply of urgently needed lipids and boost the amount of their delivery by the year-end.
FDA casts doubt on clinical meaningfulness of Merck’s Keytruda trial data pharmaceutical-technology
February 09, 2021
The US Food and Drug Administration (FDA) has cast doubt on the results from Merck’s KEYNOTE-522 trial of Keytruda (pembrolizumab) submitted to support its expanded label in treating triple-negative breast cancer (TNBC).
COVID-19 has accelerated innovation and experimentation in therapy development and clinical trials expresspharma
February 05, 2021
Sunil Punjabi, Country Speaker & Head of Research Solutions Commercial, Merck India outlines how the COVID-19 pandemic is resetting some priorities for the pharma sector and how the sector will have to transform to build more resilience to tackle ...

Previous page 1 2 3 4 5 6 7 8 9 10 ... 51 52 Next page